After-Hours Rally Sweeps Biotech Sector: Healthcare Triangle and Key Players Drive Market Momentum

Monday’s extended trading session delivered impressive gains across the biotechnology and healthcare landscape, with Healthcare Triangle, Inc. (HCTI) among the notable climbers alongside several other industry heavyweights. The sector surge reflects a combination of regulatory tailwinds and accumulated investor confidence in the space.

Novo Nordisk Leads with FDA Approval Catalyst

Novo Nordisk A/S (NVO) delivered the session’s standout performance, jumping 9.48% to $52.66 after-hours—a $4.56 gain that underscored market enthusiasm for a major regulatory breakthrough. The U.S. Food and Drug Administration (FDA) greenlit Novo Nordisk’s once-daily oral Wegovy tablet, marking the first oral GLP-1 therapeutic option approved for obesity management in the U.S. market. The approval carries dual significance: the pill is cleared for weight management when combined with dietary modifications and exercise, and critically, it demonstrated efficacy in reducing major adverse cardiovascular events—including mortality, myocardial infarction, and cerebrovascular incidents—in obese or overweight patients with established cardiovascular disease.

Healthcare Triangle Positioned for AI-Driven Expansion

Healthcare Triangle, Inc. (HCTI) advanced 6.72% to $1.43 in extended trading, buoyed by strategic developments in customer experience technology. The company announced an Advance Agreement with Teyame AI LLC, a precursor to its acquisition of Spain-domiciled entities Teyame 360 SL and Datono Mediacion SL. This move positions Healthcare Triangle to strengthen its footprint in AI-powered patient and customer engagement solutions globally.

Broad-Based Biotech Momentum Across Multiple Names

Beyond the headline movers, the sector displayed widespread strength. IDEAYA Biosciences, Inc. (IDYA) gained 6.49% to $37.81, capitalizing on recent developments in its Phase 2/3 OptimUM-02 trial, which achieved full enrollment of 435 patients evaluating darovasertib combined with Pfizer’s crizotinib for metastatic uveal melanoma. First-quarter 2026 progression-free survival data could pave the way for accelerated U.S. approval discussions.

Neumora Therapeutics, Inc. (NMRA) advanced 16.02% to $2.10, reflecting broader sector appetite despite the absence of company-specific announcements. BioRestorative Therapies, Inc. (BRTX) climbed 6.90% to $1.24, riding momentum from its November 17 Type B FDA meeting grant for potential accelerated Biologics License Application pathways targeting its Fast-Track-Designated BRTX-100 program for chronic lumbar disc disease.

RenovoRx, Inc. (RNXT) added 4.44% to $0.94 after-hours, with investors reflecting on the company’s earlier disclosure of accepted abstract submission to the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2026, with Phase III TIGeR-PaC trial findings due in January.

Measured Gains in Surgical Technology

Alphatec Holdings, Inc. (ATEC) posted a more modest 2.80% gain to $21.28, with the spine surgery technology provider maintaining investor confidence despite no fresh Monday announcements.

The session underscored how regulatory catalysts and strategic corporate developments continue to energize the biotech sector, even during periods of limited news flow for individual names.